Abstract P2-16-13: Phase I dose escalation clinical trial of the PI3K inhibitor BKM120 and capecitabine (C) in metastatic breast cancer (MBC)

2013 ◽  
Author(s):  
EC Dees ◽  
PK Marcom ◽  
A Snavely ◽  
J Noe ◽  
CK Anders ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Metastatic Breast Cancer ◽  
Phase I ◽  
Dose Escalation ◽  
Metastatic Breast ◽  
Pi3k Inhibitor

Phase I–II Vinorelbine (Navelbine®) by Continuous Infusion in Patients with Metastatic Breast Cancer: Cumulative Toxicities Limit Dose Escalation

2001 ◽  
Vol 19 (5) ◽  
pp. 459-466 ◽  
Author(s):  
Nuhad K. Ibrahim ◽  
Vicente Valero ◽  
Zia Rahman ◽  
Richard L. Theriault ◽  
Ronald S. Walters ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase I ◽  
Continuous Infusion ◽  
Dose Escalation ◽  
Metastatic Breast

scholarly journals A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer

2015 ◽  
Vol 4 (7) ◽  
pp. 1051-1059 ◽  
Author(s):  
Pavani Chalasani ◽  
Marilyn Marron ◽  
Denise Roe ◽  
Kathryn Clarke ◽  
Maria Iannone ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Metastatic Breast Cancer ◽  
Phase I ◽  
Metastatic Breast ◽  
Phase I Clinical Trial

scholarly journals A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer

2018 ◽  
Vol 18 (4) ◽  
pp. 289-297 ◽  
Author(s):  
Autumn J. McRee ◽  
Paul K. Marcom ◽  
Dominic T. Moore ◽  
William C. Zamboni ◽  
Zachary A. Kornblum ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase I ◽  
Phase I Trial ◽  
Metastatic Breast ◽  
Pi3k Inhibitor

scholarly journals A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer

2015 ◽  
Vol 112 (5) ◽  
pp. 819-824 ◽  
Author(s):  
T Sakiyama ◽  
J Tsurutani ◽  
T Iwasa ◽  
H Kawakami ◽  
Y Nonagase ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase I ◽  
Dose Escalation ◽  
Metastatic Breast ◽  
Dose Escalation Study

Clinical and biomarker results from phase I/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 1018-1018 ◽  
Author(s):  
Priyanka Sharma ◽  
Vandana Gupta Abramson ◽  
Anne O'Dea ◽  
Harsh B Pathak ◽  
Ziyan Y. Pessetto ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase I ◽  
Metastatic Breast ◽  
Pi3k Inhibitor
Sign in / Sign up

Export Citation Format

Share Document